individuals taking specific antipsychotic medications may develop TD.1
symptoms can appear after starting these medications.2
Screening for TD is often delayed — or skipped altogether. Failing to screen routinely puts patients at risk of undetected progression and exposes providers to clinical liability and compliance gaps. In today’s behavioral health landscape, meeting screening standards isn’t optional — it’s essential.
Provider Sign UpTrusted by leading behavioral health providers
“There’s always that doubt—‘Did I really see dyskinesia or was that just normal movement?’ TDScreen helps me make confident, evidence-based decisions.”
Clinically Validated
Published in the Journal of Clinical Psychiatry, a peer-reviewed study across 356 participants found that TDScreen’s AI achieved an AUC of 0.89 and surpassed the sensitivity and specificity of trained clinicians using the standard AIMS assessment.
At an optimized threshold, the model reached AUC 0.900, confirming strong agreement with expert clinician AIMS ratings.
How It Works
The TDScreen tool is based on the Abnormal Involuntary Movement Scale (AIMS), a comprehensive clinician-rated scale designed to specifically evaluate orofacial movements. Employing advanced AI video technology, TDScreen efficiently assesses and quantifies symptom presence and severity of tardive dyskinesia in less than 5 minutes. The resulting score generated by this screening can aid in clinical decision-making and management strategies.
Provider Sign Up
Request access and grant us permission to securely share patient screening results with you.
Collaborate with our team to enroll your eligible patients for regular automated screenings.
Results appear in your HIPAA-compliant provider portal and can help inform follow-up.
Patients are automatically notified to screen every 4 months, or at the frequency you choose.
Each result includes an estimated AIMS total that approximates a full clinician assessment, so findings land in the language you already chart.
A ranked list of detected movements with severity, region, and prompt. Click any moment to jump to that point in the video.
Severity and frequency across face and eyes, lips, jaw, tongue, and body, benchmarked against a reference population.
AI-assisted estimates inform your judgment; the diagnosis and care decisions stay with you.
The Patient Experience
TDScreen guides patients through a simple, non-intimidating 5-minute video assessment on their own device. No app download required — just a link you share.
Among 2,000+ patients screened with TDScreen, 80% of those diagnosed with TD were prescribed treatment…
Read Article →
Early detection and diagnosis offer the best chance to reduce the long-term impact TD can have…
Read Article →
A hidden placebo response to watch for when patients stop meds on their own…
Read Article → The first automated, video-based screening tool for tardive dyskinesia, available at no cost to providers…
Read Article →
Available free to National Council for Mental Wellbeing members and behavioral health providers…
Read Article →Clinicians can access our FREE online platform, TDScreen, designed to streamline TD risk assessment and improve patient care.
Seamlessly integrate automated TDScreen protocols alongside other essential screening and monitoring programs (additional fees may apply).
Searchable answers on privacy, validation, consent, and getting started.
Explore the FAQ →Learn what tardive dyskinesia is, how TDScreen works, and what to do if you’re concerned about your medication’s side effects.
Go to Patient Information Page →
